Catalyst
Slingshot members are tracking this event:
Achillion (ACHN) Doses First Patient in Open-Label Proof-of-Concept Phase 2 Study Evaluating ACH-4471 in Paroxysmal Nocturnal Hemoglobinuria (PNH)
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ACHN |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 06, 2017
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Open-label, Proof-of-concept Trial, Phase 2, Ach-4471, Paroxysmal Nocturnal Hemoglobinuria
